Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
corynebacterium parvum + fluorouracil + melphalan
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous, Oral, Subcutaneous, Intramuscular
01
Overview
This is a combination therapy consisting of three agents: Corynebacterium parvum, fluorouracil, and melphalan. - **Corynebacterium parvum** is a killed bacterial preparation used as an immunotherapeutic agent. It acts as a non-specific immunopotentiator by stimulating the immune system, particularly enhancing macrophage activity and increasing immunoglobulin levels, which may contribute to anti-tumor effects[1][2][3]. - **Fluorouracil (5-FU)** is an antimetabolite chemotherapy drug that inhibits thymidylate synthase, thereby interfering with DNA synthesis and function in rapidly dividing cells (not directly referenced in search results but well-established). - **Melphalan** is an alkylating agent that crosslinks DNA strands, preventing cancer cell replication and leading to cell death[4][5][6]. This combination would be considered investigational or experimental; there are no widely recognized brand names or approvals for this specific triple regimen. Each component has been studied individually or in other combinations for various cancers.
02
Targets
PRR (Pattern recognition receptors)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on corynebacterium parvum + fluorouracil + melphalan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on corynebacterium parvum + fluorouracil + melphalan.